ArticleAnnals of general psychiatry2023
Discontinuation of antidepressant treatment: a retrospective cohort study on more than 20,000 participants.
Article in Annals of general psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- The therapeutic readiness of probiotics in major depressive disorder: A systematic review of randomised controlled trials.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- Evaluation of a probiotic blend on psychosocial health and biomarkers of inflammatory, immune and stress response in adults with subthreshold depression: a double-blind, randomised, placebo-controlled trial.The British journal of nutrition · 2026Trial
- Efficacy and safety of Shugan Jieyu capsules in combination with zolpidem for insomnia disorder with depressive symptoms: a double-blind randomized controlled trial.BMC complementary medicine and therapies · 2025Trial
- Effects of Gepirone-ER on Sexual Function in Patients With Major Depressive Disorder.The Journal of clinical psychiatry · 2024Trial
- Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical Trial.Journal of clinical psychopharmacologyTrial
- Where do people obtain side effect information? Results from a census-matched U.S. national survey.Exploratory research in clinical and social pharmacy · 2026Article
- Clinical Outcomes Among Patients Taking Brexpiprazole as Augmentation with Antidepressant Treatment for Major Depressive Disorder in a United States Real-World Dataset.Neurology and therapy · 2026Article
- Long-Term Real-World Outcomes Among Patients with Major Depressive Disorder with Anxiety-Related Diagnosis Taking Brexpiprazole as Augmentation with Antidepressant Treatment.Neurology and therapy · 2026Article
- Association of pharmacotherapy with all-cause mortality among patients with irritable bowel syndrome.Communications medicine · 2026Article
- Investigating the Use of Antidepressants in Treating Major Depressive Disorder:Saudi medical journal · 2026Article
- Article
- Real-World Antidepressant Treatment Persistence in Children and Adolescents with Major Depressive Disorder in Japan: A Retrospective Nationwide Claims-Based Study.Neuropsychiatric disease and treatment · 2026Article
- Sertraline for the Treatment of Major Depressive Disorder in the US: Effectiveness and Acceptability in Real-World Practice.Neuropsychiatric disease and treatment · 2026Article
- Exploratory cluster analysis of self-reported adverse events associated with antidepressants using Gower distance and partitioning around medoids: a single-center cross-sectional study.Frontiers in psychiatry · 2026Article
- Genetic influences on antidepressant side effects: a CYP2C19 gene variation and polygenic risk study in the Estonian Biobank.European journal of human genetics : EJHG · 2025Article
- Use of Antidepressants Decreased After Initiation of ADHD Treatment in Adults-A Finnish Nationwide Register Study Describing Use of ADHD and Non-ADHD Medication in People With and Without ADHD.Acta psychiatrica Scandinavica · 2025Article
- Neuroimaging as a Tool for Advancing Pediatric Psychopharmacology.Paediatric drugs · 2025Review
- Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.Therapeutic advances in psychopharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFactors influencing antidepressant treatment discontinuation are poorly understood. In the present study, we aimed to estimate the prevalence of antidepressant treatment discontinuation and identify demographic characteristics, psychiatric comorbidities, and specific side effects associated with treatment discontinuation.
methodsWe leveraged data from the Australian Genetics of Depression Study (AGDS; N = 20,941) to perform a retrospective cohort study on antidepressant treatment discontinuation. Participants were eligible if they were over 18 years of age, had taken antidepressants in the past 4 years, and provided informed consent.
resultsAmong the ten antidepressants studied, the highest discontinuation rates were observed for Mirtazapine (57.3%) and Amitriptyline (51.6%). Discontinuation rates were comparable across sexes except for Mirtazapine, for which women were more likely to discontinue. The two most common side effects, reduced sexual function and weight gain, were not associated with increased odds of treatment discontinuation. Anxiety, agitation, suicidal thoughts, vomiting, and rashes were associated with higher odds for treatment discontinuation, as were lifetime diagnoses of PTSD, ADHD, and a higher neuroticism score. Educational attainment showed a negative (protective) association with discontinuation across medications.
conclusionsOur study suggests that not all side effects contribute equally to discontinuation. Common side effects such as reduced sexual function and weight gain may not necessarily increase the risk of treatment discontinuation. Side effects linked to discontinuation can be divided into two groups, psychopathology related and allergy/intolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.